Eton Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Eton Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Eton Pharmaceuticals Inc Strategy Report
- Understand Eton Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eton Pharmaceuticals Inc (Eton Pharmaceuticals) is a pharmaceutical company. It develops and commercializes pharmaceutical products including formulations. The company’s marketed products are Alkindi Sprinkle, Betaine Anhydrous, and Carglumic Acid. Its pipeline products include dehydrated alcohol injection, ZENEO hydrocortisone autoinjector, ET-400, and ET-500. Eton Pharmaceuticals develops its products in multiple dosage forms including liquid formulations, sterile injectables, oral liquids, and ophthalmics. The company leverages relationships with development partners in the US and Europe to create a portfolio of products. The company's products find application in therapeutic areas including endocrinology and metabolic genetics. Eton Pharmaceuticals is headquartered in Deer Park, Illinois, the US.
Headquarters
United States of America
Address
21925 W Field Pkwy Ste 235, Deer Park, Illinois, 60010-7278
Website
etonpharma.com
Telephone
1 847 7877361
No of Employees
30
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ETON (NASD)
Revenue (2022)
$31.6M
48.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
89.6%
(2022 vs 2021)
Market Cap*
$80.2M
Net Profit Margin (2022)
XYZ
93.0%
(2022 vs 2021)
* As of and is in US$
Eton Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | ZENEO |
| Alkindi Sprinkle: Endocrinology | Alkindi Sprinkle |
| Carglumic Acid Tablets: Metabolic Genetics | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Acquisitions/Mergers/Takeovers | In March, the company acquired the U.S. rights to PKU GOLIKE from Relief Therapeutics Holding SA. |
| 2023 | Contracts/Agreements | In October, the company entered into an agreement to acquire Nitisinone Capsules via Oakrum Pharma, LLC’s Chapter 11 bankruptcy proceeding. |
| 2023 | Others | In June, the company terminated its asset purchase agreement with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation as bankruptcy trustee for the bankruptcy estates of the debtors, and certain other affiliates of the debtors. |
Competitor Comparison
| Key Parameters | Eton Pharmaceuticals Inc | BioXcel Therapeutics Inc | Opiant Pharmaceuticals Inc | Innovus Pharmaceuticals Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Deer Park | New Haven | Santa Monica | San Diego |
| State/Province | Illinois | Connecticut | California | California |
| No. of Employees | 30 | 74 | - | 1 |
| Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Norbert G. Riedel | Chairman | Executive Board | 2018 | 65 |
| Sean E. Brynjelsen | Chief Executive Officer; Director | Executive Board | 2017 | 51 |
| James R. Gruber | Chief Financial Officer | Senior Management | 2022 | 51 |
| Ingrid Hoos | Senior Vice President - Scientific Affairs | Senior Management | 2020 | - |
| David C. Krempa | Chief Business Officer | Senior Management | 2023 | 34 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer